Optimata Granted Patent for Modeling Angiogenesis and Providing Optimal Treatment
Optimata Ltd. announced today that it has been granted U.S. Patent 7,418,374, entitled: “Treatment protocol generation for diseases related to angiogenesis”. The patent protects a system and methods for modeling diseases which relate to angiogenesis processes, and optimization methods to predict improved treatment regimens. Angiogenesis is a key process in the progression of different diseases such as solid tumor cancers, cardiovascular diseases, hematological disorders, and macular degeneration.
The potential to block tumor growth and metastases by angiogenesis inhibition represents an intriguing therapeutic strategy for the treatment of cancer. There are currently an unprecedented number of anti-angiogenic drugs in clinical trials. (There are 683 open interventional studies, according to the listings of the U.S. National Institute of Health). Optimata’s patent-protected technology, which comprises a computerized biosimulation system for optimizing drug therapies, is expected to benefit such studies. The patent grants Optimata protection for its proprietary technology that demonstrates simulations of the angiogenesis course and the way it is affected by diverse drugs.
The patent covers optimization methods and systems relating to mathematical models of angiogenesis, which include pro-angiogenesis and anti-angiogenesis components, e.g. the regulatory factors; vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF), angiopoietin 1, angiopoietin 2, etc. Optimata’s technology also incorporates simulation of the process of vessel maturation and related development processes; as well as the effects of a drug or a combination of drugs on each of the model components and on the outcomes for disease progression.
Optimata’s novel technology can generate a plurality of treatment regimens and select improved treatments. This can be applied to streamline the development of new drugs and to repurpose anti-angiogenic drugs whose development was suspended.
“This patent reinforces Optimata’s leadership position in the field of predictive oncology. By using the analytical power of the Optimata Virtual Patient(R) Engine drug developers will obtain early indications about the angiogenic effects of drugs in development,” said Prof. Zvia Agur, Founder and CSO of Optimata.
Optimata’s Virtual Patient(R) technology currently plays an important role in oncology drug repurposing, and also in drug development programs of major pharmaceutical companies, including Eli Lilly. Its use for personalizing several new antiangiogenic drugs, in particular Avastin, will be published in the prestigious journal Cancer Research in the autumn.
About the Optimata Virtual Patient(R)
The Optimata Virtual Patient(R) is a unique predictive biosimulation technology, comprising computer-implemented mathematical algorithms of key physiological, pathological and pharmacological processes in the body of the patient. It thoroughly unfolds drug — patient dynamic interactions, enabling drug developers to perform rapid virtual clinical trials and to clinical indication match for patient population, and to forecast optimal drug treatments for a given trial end point. Moreover, calibrated with patient-specific parameters, this technology can tailor improved treatments of various monotherapies and combination therapies of targeted and chemotherapeutic drugs. The original concepts underlying Optimata Virtual Patient(R) are protected by patents in the USA (2000) and Europe (2006) and so are the mathematical algorithms embedded in it.
About Optimata Ltd.
Optimata Ltd. is an interdisciplinary science-based company developing computerized tools — Virtual Patient engines — for navigating drug development towards better drugs, faster. Applying bio-mathematics to develop a predictive bio-simulation software toolkit, this technology provides a comprehensive drug development solution, from the pre-clinical phase through treatment personalization.
For more information visit www.optimata.com.